Increased SHMT2 positively correlates with the breast cancer grade [137] and is associated with worse relapse-free survival (RFS), distant metastases, and overall survival (OS) in breast cancer patients (N = 801) [131]. Here, SHMT2 is linked to breast carcinoma.